Killer T cell treatment shows promise against cancers in transplant patients

Blood cell donations could be used to treat transplant patients with a particular form of cancer, according to a Cancer Research UK study reported in the journal Blood¹ today (Wednesday).

A team of researchers at the University of Edinburgh generated killer T cells from healthy Scottish blood donors and injected them into patients with a type of blood cell cancer called PTLD². This form of cancer is caused by a virus in transplant patients whose immune systems have been suppressed to stop their new organ from being rejected and affects up to around 10 per cent of transplant patients.

Around two thirds of patients responded to the treatment. If further trials are successful, a single bank of T cells could potentially serve as a global source of immune cells to treat the condition.

PTLD is caused by the Epstein-Barr virus, a viral infection that over 90 per cent of adults carry. Normally the virus causes no ill effects but it can reactivate in transplant patients and cause PTLD.

Because children are less likely to have been previously exposed to the virus, they are more prone to develop PTLD when they meet the virus for the first time after transplant.

Lead researcher Dr Tanzina Haque, now at the Royal Free and University College Medical School, London, said: “EBV infection after transplantation carries a high risk of PTLD. Our results are encouraging and show that T cell therapy could present a safe alternative treatment for the disease.”

The findings of a smaller study using the same technique involving four children and four adults were published in the Lancet³ in 2002 and the treatment’s first success was for an eighteen month-old boy from West Yorkshire who developed the disease following a liver and bowel transplant.

In this study – the first phase II clinical trial⁴ of this approach to the treatment – researchers treated 33 people, ten of whom were children. They used killer T cells taken from healthy blood donors who had already been exposed to EBV. These cells naturally recognise proteins belonging to EBV and kill virus-infected PTLD cells.

After six months, 26 patients were still alive. Of these, 14 patients’ tumours had been completely destroyed. In 3 other patients, the tumours shrank to at least half their original size. Thirteen patients with initial complete response remained free of PTLD for up to 7.5 years.

Study director and team leader Professor Dorothy Crawford from University of Edinburgh said: “Current treatments for PTLD include reducing immunosuppression along with chemotherapy, radiotherapy and the drug rituximab. These are all associated with side-effects and do not always successfully treat the condition. This new treatment is proving to be effective and has no toxic effects.”

Prof Crawford added that the researchers are now planning to create a new blood bank to enable a larger scale study.

Kate Law, director of clinical trials at Cancer Research UK, said: “The results of this study are exciting for transplant patients at risk of PTLD, particularly young children who are more prone to the condition. We hope further trials using this treatment will confirm its power to help people with this type of cancer.”

ENDS

For media enquiries please contact the press office on 020 7061 8300 or, out of hours, the duty press officer on 07050 264 059.